Roche Holding AG

04/09/2024 | Press release | Distributed by Public on 04/09/2024 09:45

Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.